Hidden liver risk in type 1 diabetes: study aims to find undiagnosed cases
NCT ID NCT07475962
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will check how often fatty liver disease and liver scarring happen in adults with type 1 diabetes or LADA in Quebec. About 100 participants will get a special liver scan (FibroScan) during one visit. The goal is to find hidden liver problems that current checkups might miss.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will consist of 100 adults (aged 18 years and older) living with type 1 diabetes or LADA for at least one year.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Individuals ≥ 18 years of age. * A clinical diagnosis of type 1 diabetes or Latent Autoimmune Diabetes in Adults (LADA) for at least one year, as per the investigators' clinical judgment (confirmatory C-peptide and antibodies will not be required). Exclusion Criteria: * Alcohol consumption exceeding 20g per day in women or 30g per day in men. * Known chronic liver disease (including viral, drug-induced, Wilson disease, deficit in alpha-1-antirypsin, hemochromatosis, autoimmune hepatitis, etc.). * Evidence of cirrhosis based on a result of liver biopsy, or history of portal hypertension presented by ascites, hepatic encephalopathy or varices. * History of use of medications known to induce liver steatosis, including corticosteroids, high-dose estrogens, tamoxifen, methotrexate, amiodarone, or tetracycline. * Ongoing pregnancy. * Life expectancy of less than 5 years, as per investigators' clinical judgment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Latent autoimmune diabetes in adult (LADA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin sensors replace finger pricks for diabetes care in kenya?
- Underactive thyroid may worsen liver scarring in fatty liver disease
- Sound waves may replace the needle in liver scarring tests
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Can a new ultrasound device spot liver damage without a biopsy?
- Can a math model tune insulin pumps better than standard care?